Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference.

Jubilant Therapeutics Inc. has reported the initial dosing of patients in worldwide clinical trials for JBI-802, a CoREST inhibitor, and JBI-778, a PRMT5 inhibitor.

Maze Therapeutics announces encouraging initial human data from a Phase 1 trial involving healthy participants.

Kymera Therapeutics has begun administering doses to the initial participant in its Phase 1 clinical trial of KT-621.

Intellia Announces Encouraging Outcomes from Phase 2 Trial of NTLA-2002, a CRISPR Gene Editing Therapy for Hereditary Angioedema (HAE).

Skyhawk Therapeutics showcases impressive preclinical findings for SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Treatments Symposium.

Accent Therapeutics has received FDA approval for its IND application for ATX-559, the first oral inhibitor targeting DHX9.

Tyra Biosciences has shared preliminary clinical proof-of-concept findings for TYRA-300, a selective oral FGFR3 inhibitor.

Schrödinger shared new preclinical findings on SGR-3515 during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024).

The European Commission has approved a quadruplet treatment regimen using DARZALEX® (daratumumab)-SC for newly diagnosed multiple myeloma patients eligible for transplantation.

Under this agreement, TerSera will obtain the worldwide rights to MARGENZA® (margetuximab-cmkb).

Otsuka Reports Encouraging Interim Findings from Phase 3 Study of Sibeprenlimab for Treating IgA Nephropathy in Adults.